Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07778446 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Test CRT-402 in Refractory Autoimmune Disease

Name: A Study to Test CRT-402 in Refractory Autoimmune Disease — clinical trial record (NCT07778446)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorMyeloid Therapeutics

Started2026-08-24

View on ClinicalTrials.gov ↗

Patients with refractory autoimmune diseases often have limited treatment options and ongoing disease activity despite standard therapies. CRT-402 is an in vivo Cluster of differentiation 19 (CD19)-targeted CAR-T cell therapy designed to deplete CD19-positive B cells and promote immune system reset. This study evaluates the safety, tolerability, preliminary efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of CRT-402 in participants with active refractory systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM).

Trial Details

NCT Number	NCT07778446
Lead Sponsor	Myeloid Therapeutics Collaborators: CREATE Medicines
Conditions	Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma, Myositis
Enrollment	34 participants
Start Date	2026-08-24
Primary Completion	2028-12-01 (estimated)
Study Completion	2029-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-21